STLTinactive

SPOTLIGHT INNOVATION INC.

Healthcare·Oncology·Commercial
OncologyRare DiseaseOphthalmologyPain

SPOTLIGHT INNOVATION INC. (STLT): 5 pipeline candidates. Updated within the last hour.

9.5/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -2.54 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for SPOTLIGHT INNOVATION INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

—

Quarterly Burn

$395K

Runway

—

Revenue

$2K

Pipeline (5 candidates)

DrugPhase
crotoxinPhase 1
solx gold shuntApproved
stl-182Preclinical
venodolApproved
venodol roll-onApproved

Frequently asked questions

How many drug candidates are in SPOTLIGHT INNOVATION INC.'s pipeline?

SPOTLIGHT INNOVATION INC. (STLT) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is SPOTLIGHT INNOVATION INC.'s lead drug candidate?

SPOTLIGHT INNOVATION INC.'s most advanced tracked candidate is crotoxin (Phase 1) for Advanced Cancer.

Get the full picture on SPOTLIGHT INNOVATION INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar